



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/508,217	06/18/2004	Kathryn E. Uhrich	1435.008US1	4308

7590 01/25/2005

Schwegman Lundberg  
Woessner & Kluth  
PO Box 2938  
Minneapolis, MN 55402

EXAMINER
----------

BOYKIN, TERRESSA M

ART UNIT	PAPER NUMBER
----------	--------------

1711

DATE MAILED: 01/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

LS

<b>Office Action Summary</b>	<b>Application No.</b> 09/508,217	<b>Applicant(s)</b> UHRICH, KATHRYN E.	
	<b>Examiner</b> Terressa M. Boykin	<b>Art Unit</b> 1711	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on 9-26-03;3-8-00.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-40 is/are pending in the application.  
4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-40 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>3/00;9/04</u> . | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1711

### **Abstract**

Applicant is reminded of the proper language and format of an Abstract of the Disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 250 words. The printer will no longer accept Abstracts that are more than 25 lines, regardless of the number of words. The form and legal phraseology often used in patent claims, such as "means" and "said", should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

### **Claim Rejections - 35 USC § 102**

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:


A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

**Claims 1- 26 are rejected under 35 U.S.C. 102(b) as being anticipated by EP 0580386 see pages 2-9, Tables 1-3, and examples and claims 1-10.**

**EP 0580386** discloses an improved process for preparing an aromatic polyanhydride is disclosed. The preferred aromatic dicarboxylic acid is represented in the following formula:

Art Unit: 1711



(As well as figures 1-2 of the reference.) The aromatic polyanhydride of the reference is prepared by reacting an aromatic dicarboxylic acid with an anhydride to form an anhydride prepolymer, isolating and purifying the prepolymer, and subjecting the prepolymer to melt polycondensation conditions. The improvement specifically relates to the purification of the acid so it is essentially free of impurities before it is reacted with the anhydride. The polymers prepared from the improved process have higher molecular weights than the molecular weights achieved from the prior art processes, and exhibit outstanding thermal stability and mechanical properties. This combination of properties allows the aromatic polyanhydrides to be melt processed to prepare numerous devices. In addition, these aromatic polyanhydrides are bioabsorbable, and this attribute in combination with its ability for melt processing makes the polyanhydrides particularly well-suited for the preparation of implantable surgical devices such as wound closure devices which are designed to absorb in the body when exposed to moist bodily tissue.

With regard to claims 10, 11, 12, 13 –17 note beginning on page 5 line 46 that the polyanhydrides of the reference may be injected or molded to make implantable medical devices, especially wound closure devices. Further, with regard to applicant's claims regarding drug delivery, note claims 10 of the reference.


With regard to claim 18 note that reference discloses that "it should be apparent that block copolymers or blends with other absorbable or nonabsorbable polymer could be

Art Unit: 1711

prepared."

With regard to claims 19 - 26, the reference discloses in Figure 2:

FIG-2



wherein the second prepolymer anticipates the formula of applicants' claim 19 and the limitations therein.

**Claims 27 –40 are rejected under 35 U.S.C. 102(b) as being anticipated by JP 61186309 see abstract, and claims.**

With regard to claims 27 – 40 note that JP 61186309 discloses a composition for treating inflammation which includes a layer of maleic anhydride. The composition comprises a layer (I) and a layer (II). Layer (I) comprises (a) one or more polymer components of polyvinyl pyrrolidone, polyvinyl alcohol, alginic acid and its pharmaceutically acceptable salts, and a copolymer of maleic anhydride and methylvinyl ether, (b) an enzyme for tooth dirt, (c) a forming (sic) material, and (d) opt. other additives. The polymer components are 20-50 wt.% of total compsn. of (I).

Layer (II) comprises (A) one or more of polyvinyl pyrrolidone, polyvinyl alcohol, alginic acid and its pharmaceutically acceptable salts, and a copolymer of maleic

Art Unit: 1711

anhydride and methylvinylether, (B) one or more polymers of polyacrylic acid and its pharmaceutically acceptable salts, (C) an enzyme for tooth dirt, and (D) a forming (sic) material and other additives. The weight ratio of (A) and (B) is 70:30-95:5.

The enzyme includes dextranase, mutanase, etc. (C) includes starch, crystalline cellulose, dextrin, lactose, mannitol, sorbitol, etc.

Thus the references discloses aromatic polyanhydrides prepared from the same components as claimed by applicants as well as those employed for therapeutic use therein. Thus, in view of the above, there appears to be no significant difference between the reference(s) and that which is claimed by applicant(s). Any differences not specifically mentioned appear to be conventional. Consequently, the claimed invention cannot be deemed as novel and accordingly is unpatentable.

### Correspondence

**Please note that the cited U.S. patents and patent application publications are available for download via the Office's PAIR. As an alternate source, all U.S. patents and patent application publications are available on the USPTO web site ([www.uspto.gov](http://www.uspto.gov)), from the Office of Public Records and from commercial sources. Applicants may be referred to the Electronic Business Center (EBC) at <http://www.uspto.gov/ebc/index.html> or 1-866-217-9197.**


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Terressa Boykin whose telephone number is 571 272-1069. The examiner can normally be reached on Monday through Friday from 6:30am to 3:00pm.

Art Unit: 1711

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. The general information number for listings of personnel is ( 571-272-1700).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

tmb

  
Examiner Terressa Boykin  
Primary Examiner  
Art Unit 1711